查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1654232

美国人类原代细胞培养市场规模、份额、趋势分析报告：按产品、应用、最终用途和细分市场预测，2025-2030 年

U.S. Human Primary Cell Culture Market Size, Share & Trends Analysis Report By Product (Primary Cells, Primary Cell Culture Media), By Application, By End-use, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 90 Pages | 商品交期: 2-10个工作天内

价格

美国人类原代细胞培养市场的成长与趋势

根据Grand View Research, Inc.的最新报告，美国人类原代细胞培养市场规模预计到2030年将达到25.8亿美元，预测期间的复合年增长率为10.5%。

这一增长是由精准医疗需求的不断增长、细胞培养技术的进步以及药物发现、再生医学和个人化医疗应用的不断增加所推动的。

肿瘤学和再生医学领域日益增多的应用正在推动市场成长。原代细胞培养透过提供精确的模型来研究肿瘤行为和药物反应，在癌症研究中发挥至关重要的作用。在再生医学中，它对于干细胞疗法、组织工程和再生治疗的发展至关重要。它能够忠实地模拟人体生理学，使其成为提高研究效率、推动癌症治疗和个人化医疗的重要工具，进一步刺激了市场的扩张。这将推动预测期内美国对人类原代细胞培养的需求。

由于迫切需要精确的模型来研究 SARS-CoV-2 以及开发疫苗和治疗方法，COVID-19 疫情大大增加了美国市场对人类原代细胞培养物的需求。原代细胞培养在病毒研究和药物开发中已变得至关重要，可以更可靠地模拟人类反应。需求的激增，加上对生物医学研究的投资不断增加，加速了原代细胞培养的采用，使其成为即时和长期医疗解决方案的关键工具。

然而，原代细胞培养基、试剂和专用设备的高成本带来了重大的市场挑战。这些成本可能会限制原代细胞培养的采用，特别是在预算有限的小型研究机构和生物技术公司。对高品质耗材的持续需求和细胞培养系统的复杂设置进一步增加了营运成本，使得资源较匮乏的实验室难以充分利用这些技术。这种成本障碍可能会减缓市场成长并减少获得先进研究模型的机会。

美国人类原代细胞培养市场报告重点

  • 2024 年，原发细胞部分占据最大的市场占有率，为 35.08%。这是因为它们在各种研究应用中发挥着至关重要的作用，包括药物发现、毒性测试和个人化医疗开发。然而，预计在预测期内，原代细胞培养基的复合年增长率将最快。
  • 由于原代细胞培养在药物开发、个人化治疗和标靶治疗的进步中的应用越来越多，治疗方法开发领域在 2024 年占据了应用市场的主导地位。然而，再生医学预计在预测期内将以最快的复合年增长率成长。
  • 製药和生物技术公司部门在最终用途部门占据主导地位，2024 年的份额最大，为 49.27%。然而，预计预测期内 CMO 和 CRO 将以最快的复合年增长率成长。

目录

第一章调查方法与范围

第 2 章执行摘要

第 3 章市场变数、趋势与范围

  • 市场体系展望
    • 母市场展望
    • 相关/附随市场展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 美国人类原代细胞培养市场分析工具
    • 产业分析 – 波特五力分析
    • PESTEL 分析
    • COVID-19影响分析

第 4 章美国人类原代细胞培养市场：按产品分類的估计和趋势分析

  • 产品细分仪表板
  • 美国人类原代细胞培养市场的产品差异分析
  • 2018 年至 2030 年美国人类原代细胞培养市场规模及产品趋势分析
  • 原代细胞
    • 原代细胞市场，2018 - 2030
    • 造血细胞
    • 皮肤细胞
    • 肝细胞
    • 消化道细胞
    • 肺细胞
    • 肾臟细胞
    • 心臟细胞
    • 骨骼细胞和肌肉细胞
    • 其他原代细胞
  • 试剂和补充剂
    • 试剂和补充剂市场，2018-2030 年
    • 无血清培养基
    • 含血清培养基
    • 其他的
  • 原代细胞培养基
    • 2018 年至 2030 年原代细胞培养基市场
    • 附件解决方案
    • 缓衝液和盐
    • 形成
    • 生长因子和细胞激素
    • 其他的

第 5 章美国人类原代细胞培养市场：按应用的估计和趋势分析

  • 应用程式细分仪表板
  • 美国人类原代细胞培养市场使用趋势分析
  • 2018 年至 2030 年美国人类原代细胞培养市场规模及应用趋势分析
  • 药物研发
    • 2018 至 2030 年药物研发市场
  • 治疗方法进展
    • 治疗方法开发市场，2018 - 2030 年
  • 再生医学
    • 再生医学市场，2018 - 2030
  • 其他的
    • 其他市场，2018-2030

第六章美国人类原代细胞培养市场依最终用途、估计和趋势分析

  • 最终用途细分仪表板
  • 美国人类原代细胞培养市场最终用途变化分析
  • 2018 年至 2030 年美国人类原代细胞培养市场规模及趋势分析（依最终用途）
  • 製药及生技公司
    • 2018-2030 年製药与生技市场
  • CMO 和 CRO
    • CMO 与 CRO 市场，2018 年至 2030 年
  • 学术研究所
    • 学术研究市场，2018-2030

第七章 竞争格局

  • 公司分类
  • 战略地图
  • 公司简介/上市公司
    • Thermo Fisher Scientific, Inc.
    • Merck KGaA
    • Lonza Group
    • Corning Incorporated
    • Danaher Corporation
    • QIAGEN NV
    • STEMCELL Technologies
    • Becton, Dickinson, and Company（BD）
    • Bio-Techne Corporation
    • Charles River Laboratories
Product Code: GVR-4-68040-501-4

U.S. Human Primary Cell Culture Market Growth & Trends:

The U.S. human primary cell culture market size is anticipated to reach USD 2.58 billion by 2030 and is anticipated to expand at a CAGR of 10.5% during the forecast period, according to a new report by Grand View Research, Inc. This growth is driven by increasing demand for precision medicine, advancements in cell culture technologies, and rising applications in drug discovery, regenerative medicine, and personalized healthcare.

The expanding applications in oncology and regenerative medicine are driving market growth. Primary cell cultures play a crucial role in cancer research by providing accurate models for studying tumor behavior and drug responses. In regenerative medicine, they are essential for developing stem cell therapies, tissue engineering, and regenerative treatments. Their ability to closely mimic human physiology enhances research efficiency, making them indispensable tools in advancing cancer therapies and personalized treatments, further fueling the market's expansion. Thereby propelling the demand for human primary cell culture in the U.S. over the forecast period.

The COVID-19 pandemic substantially boosted the demand for human primary cell culture in the U.S. market, driven by the urgent need for accurate models to study SARS-CoV-2 and develop vaccines and therapeutic treatments. Primary cell cultures became essential in virus research and drug development, enabling more reliable simulations of human responses. This surge in demand, coupled with increased investments in biomedical research, accelerated the adoption of primary cell cultures, positioning them as a key tool in both immediate and long-term healthcare solutions.

However, the high costs associated with primary cell culture media, reagents, and specialized equipment pose a significant market challenge. These expenses can limit the adoption of primary cell cultures, especially among smaller research institutions and biotech companies with constrained budgets. The ongoing need for premium-quality supplies and the complex setup for cell culture systems can further increase operational costs, making it difficult for less-funded entities to fully leverage these technologies. This cost barrier could slow the market's growth and reduce accessibility to advanced research models.

U.S. Human Primary Cell Culture Market Report Highlights:

  • The primary cells segment held the largest market share of 35.08% in 2024. This is attributed to their essential role in drug discovery, toxicity testing, and personalized medicine development across various research applications. However, primary cell culture media is anticipated to grow at the fastest CAGR over the forecast period
  • The therapy development segment dominated the application market in 2024, driven by the increasing use of primary cell cultures in drug development, personalized treatments, and the advancement of targeted therapies. However, regenerative medicine is anticipated to grow at the fastest CAGR over the forecast period
  • The pharmaceutical & biotechnology companies segment dominated the end use segment with the largest share of 49.27% in 2024. However, CMOs & CROs are expected to grow at the fastest CAGR over the forecast period

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
    • 1.2.1. Product Segment
    • 1.2.2. Application Segment
    • 1.2.3. End Use Segment
  • 1.3. Information analysis
  • 1.4. Market formulation & data visualization
  • 1.5. Data validation & publishing
  • 1.6. Information Procurement
    • 1.6.1. Primary Research
  • 1.7. Information or Data Analysis
  • 1.8. Market Formulation & Validation
  • 1.9. Market Model
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of chronic and infectious diseases
      • 3.2.1.2. Growing focus on personalized medicine
      • 3.2.1.3. Technological innovations in 3D cell culture
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High costs of primary cells
  • 3.3. U.S. Human Primary Cell Culture Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. U.S. Human Primary Cell Culture Market: Product Estimates & Trend Analysis

  • 4.1. Product Segment Dashboard
  • 4.2. U.S. Human Primary Cell Culture Market Product Movement Analysis
  • 4.3. U.S. Human Primary Cell Culture Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
  • 4.4. Primary Cells
    • 4.4.1. Primary Cells Market, 2018 - 2030 (USD Million)
    • 4.4.2. Hematopoietic Cells
      • 4.4.2.1. Hematopoietic Cells Market, 2018 - 2030 (USD Million)
    • 4.4.3. Skin Cells
      • 4.4.3.1. Skin Cells Market, 2018 - 2030 (USD Million)
    • 4.4.4. Hepatocytes
      • 4.4.4.1. Hepatocytes Market, 2018 - 2030 (USD Million)
    • 4.4.5. Gastrointestinal Cells
      • 4.4.5.1. Gastrointestinal Cells Market, 2018 - 2030 (USD Million)
    • 4.4.6. Lung Cells
      • 4.4.6.1. Lung Cells Market, 2018 - 2030 (USD Million)
    • 4.4.7. Renal Cells
      • 4.4.7.1. Renal Cells Market, 2018 - 2030 (USD Million)
    • 4.4.8. Heart Cells
      • 4.4.8.1. Heart Cells Market, 2018 - 2030 (USD Million)
    • 4.4.9. Skeletal and Muscle Cells
      • 4.4.9.1. Skeletal and Muscle Cells Market, 2018 - 2030 (USD Million)
    • 4.4.10. Other Primary Cells
      • 4.4.10.1. Other Primary Cells Market, 2018 - 2030 (USD Million)
  • 4.5. Reagents & Supplements
    • 4.5.1. Reagents & Supplements Market, 2018 - 2030 (USD Million)
    • 4.5.2. Serum-free Media
      • 4.5.2.1. Serum-free Media Market, 2018 - 2030 (USD Million)
    • 4.5.3. Serum-containing Media
      • 4.5.3.1. Serum-containing Media Market, 2018 - 2030 (USD Million)
    • 4.5.4. Others
      • 4.5.4.1. Others Market, 2018 - 2030 (USD Million)
  • 4.6. Primary Cell Culture Media
    • 4.6.1. Primary Cell Culture Media Market, 2018 - 2030 (USD Million)
    • 4.6.2. Attachment Solutions
      • 4.6.2.1. Attachment Solutions Market, 2018 - 2030 (USD Million)
    • 4.6.3. Buffers and Salts
      • 4.6.3.1. Buffers and Salts Market, 2018 - 2030 (USD Million)
    • 4.6.4. Sera
      • 4.6.4.1. Sera Market, 2018 - 2030 (USD Million)
    • 4.6.5. Growth Factors and Cytokines
      • 4.6.5.1. Growth Factors and Cytokines Market, 2018 - 2030 (USD Million)
    • 4.6.6. Others
      • 4.6.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 5. U.S. Human Primary Cell Culture Market: Application Estimates & Trend Analysis

  • 5.1. Application Segment Dashboard
  • 5.2. U.S. Human Primary Cell Culture Market Application Movement Analysis
  • 5.3. U.S. Human Primary Cell Culture Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
  • 5.4. Drug Discovery
    • 5.4.1. Drug Discovery Market, 2018 - 2030 (USD Million)
  • 5.5. Therapy Development
    • 5.5.1. Therapy Development Market, 2018 - 2030 (USD Million)
  • 5.6. Regenerative Medicine
    • 5.6.1. Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • 5.7. Others
    • 5.7.1. Others Market, 2018 - 2030 (USD Million)

Chapter 6. U.S. Human Primary Cell Culture Market: End Use Estimates & Trend Analysis

  • 6.1. End Use Segment Dashboard
  • 6.2. U.S. Human Primary Cell Culture Market End Use Movement Analysis
  • 6.3. U.S. Human Primary Cell Culture Market Size & Trend Analysis, by End Use, 2018 to 2030 (USD Million)
  • 6.4. Pharmaceutical & Biotechnology Companies
    • 6.4.1. Pharmaceutical & Biotechnology Companies Market, 2018 - 2030 (USD Million)
  • 6.5. CMOs & CROs
    • 6.5.1. CMOs & CROs Market, 2018 - 2030 (USD Million)
  • 6.6. Academic Research Institutes
    • 6.6.1. Academic Research Institutes Market, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Company Categorization
  • 7.2. Strategy Mapping
  • 7.3. Company Profiles/Listing
    • 7.3.1. Thermo Fisher Scientific, Inc.
      • 7.3.1.1. Overview
      • 7.3.1.2. Financial Performance
      • 7.3.1.3. Product Benchmarking
      • 7.3.1.4. Strategic Initiatives
    • 7.3.2. Merck KGaA
      • 7.3.2.1. Overview
      • 7.3.2.2. Financial Performance
      • 7.3.2.3. Product Benchmarking
      • 7.3.2.4. Strategic Initiatives
    • 7.3.3. Lonza Group
      • 7.3.3.1. Overview
      • 7.3.3.2. Financial Performance
      • 7.3.3.3. Product Benchmarking
      • 7.3.3.4. Strategic Initiatives
    • 7.3.4. Corning Incorporated
      • 7.3.4.1. Overview
      • 7.3.4.2. Financial Performance
      • 7.3.4.3. Product Benchmarking
      • 7.3.4.4. Strategic Initiatives
    • 7.3.5. Danaher Corporation
      • 7.3.5.1. Overview
      • 7.3.5.2. Financial Performance
      • 7.3.5.3. Product Benchmarking
      • 7.3.5.4. Strategic Initiatives
    • 7.3.6. QIAGEN N.V.
      • 7.3.6.1. Overview
      • 7.3.6.2. Financial Performance
      • 7.3.6.3. Product Benchmarking
      • 7.3.6.4. Strategic Initiatives
    • 7.3.7. STEMCELL Technologies
      • 7.3.7.1. Overview
      • 7.3.7.2. Financial Performance
      • 7.3.7.3. Product Benchmarking
      • 7.3.7.4. Strategic Initiatives
    • 7.3.8. Becton, Dickinson, and Company (BD)
      • 7.3.8.1. Overview
      • 7.3.8.2. Financial Performance
      • 7.3.8.3. Product Benchmarking
      • 7.3.8.4. Strategic Initiatives
    • 7.3.9. Bio-Techne Corporation
      • 7.3.9.1. Overview
      • 7.3.9.2. Financial Performance
      • 7.3.9.3. Product Benchmarking
      • 7.3.9.4. Strategic Initiatives
    • 7.3.10. Charles River Laboratories
      • 7.3.10.1. Overview
      • 7.3.10.2. Financial Performance
      • 7.3.10.3. Product Benchmarking
      • 7.3.10.4. Strategic Initiatives

List of Tables

  • TABLE 1. U.S. human primary cell culture market estimates & forecasts
  • TABLE 2. U.S. human primary cell culture market estimates & forecasts, by product, 2018 - 2030 (USD Million)
  • TABLE 3. U.S. human primary cell culture market estimates & forecasts, by application, 2018 - 2030 (USD Million)
  • TABLE 4. U.S. human primary cell culture market estimates & forecasts, by end use, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market snapshot
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Market trends & outlook
  • Fig. 7 Market segmentation & scope
  • Fig. 8 Market driver relevance analysis (Current & future impact)
  • Fig. 9 Market restraint relevance analysis (Current & future impact)
  • Fig. 10 PESTLE Analysis
  • Fig. 11 Porter's Five Forces Analysis
  • Fig. 12 Strategy framework
  • Fig. 13 Participant categorization
  • Fig. 14 U.S. human primary cell culture market: Product outlook key takeaways
  • Fig. 15 U.S. human primary cell culture market: Product movement analysis
  • Fig. 16 Primary cells market, 2018 - 2030 (USD Million)
  • Fig. 17 Hematopoietic cells market, 2018 - 2030 (USD Million)
  • Fig. 18 Skin cells market, 2018 - 2030 (USD Million)
  • Fig. 19 Hepatocytes market, 2018 - 2030 (USD Million)
  • Fig. 20 Gastrointestinal cells market, 2018 - 2030 (USD Million)
  • Fig. 21 Lung cells market, 2018 - 2030 (USD Million)
  • Fig. 22 Renal cells market, 2018 - 2030 (USD Million)
  • Fig. 23 Heart cells market, 2018 - 2030 (USD Million)
  • Fig. 24 Skeletal and muscle cells market, 2018 - 2030 (USD Million)
  • Fig. 25 Other primary cells market, 2018 - 2030 (USD Million)
  • Fig. 26 Primary cell culture media market, 2018 - 2030 (USD Million)
  • Fig. 27 Serum-free media market, 2018 - 2030 (USD Million)
  • Fig. 28 Serum-containing media market, 2018 - 2030 (USD Million)
  • Fig. 29 Others market, 2018 - 2030 (USD Million)
  • Fig. 30 Reagents and supplements market, 2018 - 2030 (USD Million)
  • Fig. 31 Attachment solutions market, 2018 - 2030 (USD Million)
  • Fig. 32 Buffers and salts market, 2018 - 2030 (USD Million)
  • Fig. 33 Sera market, 2018 - 2030 (USD Million)
  • Fig. 34 Growth factors and cytokines market, 2018 - 2030 (USD Million)
  • Fig. 35 Others market, 2018 - 2030 (USD Million)
  • Fig. 36 U.S. human primary cell culture market: Application outlook key takeaways
  • Fig. 37 U.S. human primary cell culture market: Application movement analysis
  • Fig. 38 Drug discovery market, 2018 - 2030 (USD Million)
  • Fig. 39 Therapy development market, 2018 - 2030 (USD Million)
  • Fig. 40 Regenerative medicines market, 2018 - 2030 (USD Million)
  • Fig. 41 Others market, 2018 - 2030 (USD Million)
  • Fig. 42 U.S. human primary cell culture market: End use outlook key takeaways
  • Fig. 43 U.S. human primary cell culture market: End use movement analysis
  • Fig. 44 Pharmaceutical & biotechnology companies market, 2018 - 2030 (USD Million)
  • Fig. 45 CMOs & CROs, 2018 - 2030 (USD Million)
  • Fig. 46 Academic research institutes, 2018 - 2030 (USD Million)
  • Fig. 47 U.S. human primary cell culture market, 2018 - 2030 (USD Million)
  • Fig. 48 Key companies profiled